Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Murilo Luz

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
The Prostate|September 2, 2011
Refining the orthotopic dog prostate cancer (DPC)-1 model to better bridge the gap between rodents and menMaurice Anidjar, Eleonora Scarlata, Fabio L Cury, et al.
Revista Da Associacao Medica Brasileira (1992)|October 15, 2015
Adjuvant radiotherapy versus observation alone, after radical prostatectomy in high risk prostate cancerAndrea Petruzziello, Massakazu Kato, Lais Cristine Nienkotter, et al.
World Journal of Surgical Oncology|September 10, 2014
Surgical results of pelvic exenteration in the treatment of gynecologic cancerAndrea Petruzziello, William Kondo, Sergio B Hatschback, et al.
BMC Urology|July 26, 2019
Improving ultrasound-based prostate volume estimationSaro Aprikian, Murilo Luz, Fadi Brimo, et al.
The New England Journal of Medicine|February 15, 2019
Darolutamide in Nonmetastatic, Castration-Resistant Prostate CancerKarim Fizazi, Neal Shore, Teuvo L Tammela, et al.
The New England Journal of Medicine|September 9, 2020
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with DarolutamideKarim Fizazi, Neal Shore, Teuvo L Tammela, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2021
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trialMatthew R Smith, Neal Shore, Teuvo L Tammela, et al.
European Urology|December 16, 2022
Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022]Martin Bögemann, Neal D Shore, Matthew R Smith, et al.
European Urology|September 11, 2022
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS TrialMartin Bögemann, Neal D Shore, Matthew R Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|November 4, 2024
Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS studyNeal D Shore, Karim Fizazi, Teuvo L J Tammela, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
The Prostate|September 2, 2011
Refining the orthotopic dog prostate cancer (DPC)-1 model to better bridge the gap between rodents and menMaurice Anidjar, Eleonora Scarlata, Fabio L Cury, et al.
Revista Da Associacao Medica Brasileira (1992)|October 15, 2015
Adjuvant radiotherapy versus observation alone, after radical prostatectomy in high risk prostate cancerAndrea Petruzziello, Massakazu Kato, Lais Cristine Nienkotter, et al.
World Journal of Surgical Oncology|September 10, 2014
Surgical results of pelvic exenteration in the treatment of gynecologic cancerAndrea Petruzziello, William Kondo, Sergio B Hatschback, et al.
BMC Urology|July 26, 2019
Improving ultrasound-based prostate volume estimationSaro Aprikian, Murilo Luz, Fadi Brimo, et al.
The New England Journal of Medicine|February 15, 2019
Darolutamide in Nonmetastatic, Castration-Resistant Prostate CancerKarim Fizazi, Neal Shore, Teuvo L Tammela, et al.
The New England Journal of Medicine|September 9, 2020
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with DarolutamideKarim Fizazi, Neal Shore, Teuvo L Tammela, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2021
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trialMatthew R Smith, Neal Shore, Teuvo L Tammela, et al.
European Urology|December 16, 2022
Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022]Martin Bögemann, Neal D Shore, Matthew R Smith, et al.
European Urology|September 11, 2022
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS TrialMartin Bögemann, Neal D Shore, Matthew R Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|November 4, 2024
Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS studyNeal D Shore, Karim Fizazi, Teuvo L J Tammela, et al.
Pageof 2